← Back to Home

Sudarshan plans to acquire 9.5% stake in MedTherapy, expanding into CAR-T manufacturing services across the US and India

The minority equity investment would extend the Indian pharmaceutical company's reach into cancer cell therapy. However, subsequent disclosures in September indicated that the transaction remained under due diligence, with pricing and closing yet to be finalized.

By SURL BioNews

Expansion in the cancer cell therapy industry is also taking place in manufacturing and development services. Indian pharmaceutical company Sudarshan Pharma Industries plans to acquire a 9.5% stake in MedTherapy Biotechnology, expanding its cell and gene therapy-related business through a company operating across the United States and India. The plan has board support, but procedural steps remain before formal closing.

Sudarshan's board approved the investment proposal on September 5, 2026, with plans to purchase approximately 2.424 million ordinary shares in MedTherapy. After Business Standard reported the news on September 7, a syndicated PNN release published by Pharmabiz and Outlook Business disclosed the same stake. The company's two promoters, Hemal Mehta and Sachin Mehta, also each plan to acquire a 1.5% stake. These two personal investments are calculated separately from the company's 9.5% holding.

The transaction's progress requires careful interpretation in light of subsequent disclosures. On September 15, Mint cited a company update stating that the investment proposals from both the company and its two promoters remained under due diligence and were also awaiting confirmation and resolutions from MedTherapy's board. Under the disclosed plan, the acquisition would be paid for in cash in US dollars, with the price determined according to valuation guidelines and completion targeted before March 31, 2027. The information currently available does not specify a total transaction value.

MedTherapy's cell therapy development and manufacturing services are central to its investment appeal. According to Pharmabiz reporting and company disclosures, the Boston-based company, founded in 2018, operates an integrated CAR-T cell contract development and manufacturing organization (CDMO), with a commercial-scale manufacturing facility in New Delhi that complies with good manufacturing practice (GMP) requirements, and technology development activities in Boston. These descriptions of its facilities and operations come from company materials and do not establish that any particular therapy has received marketing approval.

For Sudarshan, whose existing business includes active pharmaceutical ingredient manufacturing and trading in chemicals and solvents, this represents a step into cell and gene therapy services. The company's stated objectives include entering the US market, accessing MedTherapy's existing customers, contracts and distribution channels, and expanding its products and services. However, current disclosures do not explain what specific collaboration rights the minority stake itself would confer.

MedTherapy's corporate goals include improving the affordability of and access to cancer treatment, but the materials for this investment provide no data on treatment prices, the extent of cost reductions or clinical outcomes. At this stage, the news concerns an industry investment that remains to be completed. Whether it can translate into additional manufacturing business, or ultimately into treatments that patients can access more easily, still requires support from specific contracts, operational results and clinical evidence.

References

  1. Business Standard
  2. Pharmabiz
  3. Mint
  4. Outlook Business / PNN syndicated release